Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 11/20 | 0.39 |
| ▸ | DRD4 | P21917 | 10/20 | 0.39 |
| ▸ | DRD3 | P35462 | 10/20 | 0.39 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.39 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | HTR7 | P34969 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
| ▸ | TACR1 | P25103 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL102543 | 1.00 | MEN1 (0.47) | MEN1GAAKMT2ALTA4HDRD2 | |
| SCHEMBL106508 | 0.85 | MEN1 (0.39) | MEN1GAAKMT2ALTA4HDRD2 | |
| SCHEMBL106509 | 0.85 | MEN1 (0.39) | MEN1GAAKMT2ALTA4HDRD2 | |
| SCHEMBL103640 | 0.81 | MEN1 (0.47) | MEN1GAAKMT2ALTA4HDRD2 | |
| SCHEMBL103639 | 0.81 | MEN1 (0.47) | MEN1GAAKMT2ALTA4HDRD2 | |
| SCHEMBL102930 | 0.79 | DRD2 (0.47) | MEN1GAAKMT2ADRD2DRD4 | |
| SCHEMBL102932 | 0.79 | DRD2 (0.47) | MEN1GAAKMT2ADRD2DRD4 | |
| SCHEMBL103483 | 0.77 | MEN1 (0.42) | MEN1GAAKMT2ADRD2DRD4 | |
| SCHEMBL103125 | 0.76 | PDK1 (0.41) | — | |
| SCHEMBL103126 | 0.76 | PDK1 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2426113-B1 | CARBINOL COMPOUND HAVING HETEROCYCLIC LINKER | KOWA CO (JP) | 2013-11-06 | — | — | EP | disclosed |
| US-8551985-B2 | Carbinol derivatives having heterocyclic linker | KOWA COMPANY, LTD. (JP) | 2013-10-08 | — | — | US | disclosed |
| EP-2426113-A1 | CARBINOL COMPOUND HAVING HETEROCYCLIC LINKER | Kowa Company, Ltd. (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-20100280013-A1 | CARBINOL DERIVATIVES HAVING HETEROCYCLIC LINKER | KOWA COMPANY, LTD. (JP) | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280013-A1 | CARBINOL DERIVATIVES HAVING HETEROCYCLIC LINKER | NR1H2, NR1H3, CCR2 | MEN1 3479/4885GAA 2147/4885KMT2A 2327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.